Amer Zeidan/yalemedicine.org
Jun 17, 2025, 10:34
Amer Zeidan: Long Awaited Results of VERONA in Higher Risk MDS
Amer Zeidan, Chief of the Division of Hematologic Malignancies and Professor of Medicine at Yale University, shared a post on X:
“Long awaited results of VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk MDS. Subgroup analyses will be important.”
More posts featuring Amer Zeidan on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 17, 2025, 10:34
Jun 17, 2025, 10:05
Jun 17, 2025, 09:59
Jun 17, 2025, 09:57
Jun 17, 2025, 09:45
Jun 17, 2025, 09:28
Jun 17, 2025, 09:11